Streetbeat News

Price Targets

FG

Piper Sandler analyst John Barnidge has initiated coverage on F&G Annuities & Life (NYSE:FG) with a Neutral rating and set a price target of $48 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 12:12 pm

GLYC

Capital One analyst Zegbeh Jallah has initiated coverage on GlycoMimetics (NASDAQ:GLYC) with an Overweight rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 12:09 pm

CCL

Stifel analyst Steven Wieczynski has maintained a Buy rating on Carnival Corporation & plc (NYSE:CCL) and increased the price target from $22 to $25, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 12:09 pm

DUK

B of A Securities analyst Julien Dumoulin-Smith has maintained a Buy rating on Duke Energy (NYSE:DUK) but lowered the price target from $104 to $103.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 12:07 pm

CTAS

Stifel analyst Shlomo Rosenbaum has maintained a Hold rating on Cintas (NASDAQ:CTAS) and increased the price target from $526 to $585.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 12:06 pm

CVS

Analysts have provided mixed ratings for CVS Health (NYSE:CVS) over the past three months, with the most recent ratings being more bullish. The average 12-month price target for CVS is $93.2, down from the previous $101.00, indicating a potential decrease in stock value. CVS Health operates a vast network of retail pharmacies, is a major pharmacy benefit manager, and owns a top-tier health insurer. The company's recent acquisition of Oak Street Health could synergize with its existing operations. Financially, CVS has shown solid revenue growth, exceptional net margin, and strong ROE and ROA, with a sound debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 12:00 pm

ALPN

Alpine Immune Sciences (NASDAQ:ALPN) has been the subject of diverse analyst ratings over the past three months, with 7 analysts offering views ranging from bullish to bearish. The average 12-month price target has increased by 37.28% to $24.71, with a high estimate of $32.00 and a low of $18.00. Analysts from firms like HC Wainwright & Co., Wedbush, RBC Capital, Morgan Stanley, and Berenberg have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Alpine Immune Sciences is a clinical-stage biopharmaceutical company with a focus on protein-based immunotherapies. Despite a market capitalization below industry benchmarks, the company has seen a revenue growth of 20.03% and has a strong net margin and ROE, with minimal reliance on debt financing.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 12:00 pm

AVDX

AvidXchange Holdings (NASDAQ:AVDX) has received mixed analyst ratings over the last three months, with a current average 12-month price target of $11.67, down from $12.60. Analysts from firms like Barclays, BTIG, BMO Capital, Wells Fargo, Susquehanna, and Piper Sandler have provided various ratings and price target adjustments, reflecting changes in market conditions and company performance. AvidXchange has shown a revenue growth rate of 19.74% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -8.2%, ROE of -1.25%, and ROA of -0.38%.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 12:00 pm

TDY

Teledyne Technologies (NYSE:TDY) received varied analyst ratings over the past quarter, with 4 bullish ratings. The average 12-month price target is $481.75, up from $455.00, with a high estimate of $522.00 and a low of $455.00. James Ricchiuti of Needham raised the target from $455.00 to $522.00 and maintained a 'Buy' rating. Teledyne's revenue grew by 2.85% as of September 30, 2023, with a net margin of 14.16% and an ROE of 2.3%. The company has a low debt-to-equity ratio of 0.37, indicating prudent financial management.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 12:00 pm

ADI

Analog Devices (NASDAQ:ADI) has been the subject of diverse analyst ratings over the past three months, with 9 analysts offering ratings from bullish to bearish. The average 12-month price target is $204.0, a slight increase from the previous $201.75. Analysts from firms including Oppenheimer, Piper Sandler, Susquehanna, UBS, Truist Securities, and Morgan Stanley have adjusted their ratings and price targets, reflecting their current views on the company's performance. Analog Devices faces challenges with a revenue decline of -16.36% as of October 31, 2023, and below-average net margin and ROE compared to industry peers. However, the company has a sound financial structure with a low debt-to-equity ratio of 0.2.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 12:00 pm